Endocrine therapies in breast cancer / edited by Aman U. Buzdar.

Contributor(s):

Buzdar, Aman U

Material type: Text

TextSeries: Oxford oncology libraryPublication details: Oxford ; New York : Oxford University Press, 2007.Description: 1 online resource (viii, 120 pages) : illustrationsContent type:

text

Media type:

computer

Carrier type:

online resource

ISBN:

9780191575174
0191575178

Subject(s): Genre/Form:

Electronic books.

Additional physical formats: Print version:: Endocrine therapies in breast cancer.DDC classification:

616.99/449071 22

LOC classification:

RC280.B8 E523 2007eb

NLM classification:

WP 870

Online resources:

Click here to access online

Contents:

Selection of patients for endocrine therapies / W. Fraser Symmans and Lajos Pusztai -- Ovarian ablation / Kellie l. Jones -- Antioestrogens / John F. Forbes -- Aromatase inhibitors in early and advanced disease / Laura Boehnke Michaud -- Fulvestrant in metastatic disease / Amit Agrawal, J.F.R. Robertson, and K.L. Cheung -- Progestins and androgens / Janet l. Espirito -- Combined endocrine and chemotherapy in breast cancer / Ishmael Jaiyesimi [and others] -- Hormone replacement therapy in patients with a prior history of breast cancer / Gilbert G. Fareau and Rena Vassilopoulou-Sellin -- Chemoprevention / Saheenah Dawood and Jack Cuzick.

Summary: Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able toreduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging.

Item type:

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Home library	Collection	Call number	Materials specified	Status	Date due	Barcode
Electronic-Books	OPJGU Sonepat- Campus	E-Books EBSCO			Available

Includes bibliographical references and index.

Print version record.

Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able toreduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging.

eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - Worldwide

There are no comments on this title.

to post a comment.